Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K233788
    Date Cleared
    2024-02-13

    (77 days)

    Product Code
    Regulation Number
    892.1550
    Reference & Predicate Devices
    N/A
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    EPIQ:
    The intended use of EPIQ Ultrasound Diagnostic System is diagnostic ultrasound imaging and fluid flow analysis of the human body, with the following indications for use:

    Abdominal, Cardiac Adult, Cardiac other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), intra-luminal, intra-cardiac echo, Musculoskeletal (Conventional), Musculoskeletal (Superficial), Ophthalmic, Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transvaginal, Lung.

    The clinical environments where EPIQ Series Diagnostic Ultrasound Systems can be used include clinics, hospitals, and clinical point-of-care for diagnosis of patients.

    When integrated with Philips EchoNavigator, the systems can assist the interventionalist and surgeon with image quidance during treatment of cardiovascular disease in which the procedure uses both live X-ray and live echo guidance.

    The systems are intended to be installed, used, and operated only in accordance with the safety procedures and operating instructions given in the product user information. Systems are to be operated only by appropriately trained healthcare professionals for the purposes for which they were designed. However, nothing stated in the user information reduces your responsibility for sound clinical judgement and best clinical procedure.

    Affiniti:
    The intended use of Affiniti Series Diagnostic Ultrasound Systems is diagnostic ultrasound imaging and fluid flow analysis of the human body, with the following indications for use:

    Abdominal, Cardiac Adult, Cardiac Other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), Musculoskeletal (Conventional), Musculoskeletal (Superficial), Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transrectal, Transvaginal, Lung.

    The clinical environments where the Affiniti diagnostic ultrasound systems can be used include clinics, hospitals, and clinical point-of-care for diagnosis of patients.

    The systems are intended to be installed, used, and operated only in accordance with the safety procedures and operating instructions given in the product user information. Systems are to be operated only by appropriately trained healthcare professionals for the purposes for which they were designed. However, nothing stated in the user information reduces your responsibility for sound clinical judgement and best clinical procedure.

    Device Description

    The purpose of this Traditional 510(k) Pre-Market Notification is to introduce the Smart Doppler View ID software feature onto the EPIQ and Affiniti Series Diagnostic Ultrasound Systems.

    The purpose of the Smart Doppler View ID feature is to enhance the user's workflow through providing automation of the navigation of the touch screen groups on the Ultrasound System associated with Dopler Measurements. Without the Smart Doppler View ID feature, users must manually navigate to the desired Doppler Calculation Package Group on the Ultrasound System's various screens to perform a measurement. The Smart Doppler View ID feature automates this navigation and selects the associated calculation package group for the user based on the provided Doppler Spectrum acquired by the user using an artificial intelligence-based algorithm.

    Smart Doppler View ID maps to six Doppler Calculations Package groups on the Ultrasound System screen:

    • Aortic Valve
    • Mitral Valve
    • Tricuspid Valve
    • Pulmonic Valve
    • Venous Flow
    • TDI Vel (Tissue Doppler Imaging Velocity) & Ratio

    No hardware changes to the EPIQ or Affiniti systems are required when using the Smart Doppler View ID feature, and existing, commercialized Philips transducers are used for the Smart Doppler View ID feature.

    The feature is supported by all EPIQ and Affiniti models running software version 11.0 or higher including EPIQ CVx/CVxi, EPIQ Elite Advanced, EPIQ 7, EPIQ 5, Affiniti CVx, Affiniti 70, Affiniti 50, and Affiniti 30. The Smart Doppler View ID feature is associated with the cardiac adult indication.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study details for the Smart Doppler View ID feature, based on the provided text:

    1. Acceptance Criteria and Reported Device Performance

    Acceptance CriteriaReported Device Performance
    Algorithm Accuracy97.5% (95% CI 96.3%, 98.3%), p-value < 0.0001

    2. Sample Size for Test Set and Data Provenance

    • Sample Size (Test Set): 1100 TTE (transthoracic echo) cardiac clips
    • Number of Subjects: 400 subjects
    • Data Provenance: Retrospective, collected from a US-based hospital.

    3. Number of Experts and Qualifications for Ground Truth Establishment

    • Number of Experts: 16 cardiac sonographers, and board-certified cardiologists.
    • Qualifications of Experts:
      • Cardiac Sonographers: Possessed a high level of expertise in acquiring Doppler TTE clips.
      • Board-Certified Cardiologists: Successfully passed the National Board of Echocardiography Examination and vetted and interpreted the studies.

    4. Adjudication Method for the Test Set

    The document does not explicitly describe a formal adjudication method (like 2+1 or 3+1). However, it states that the ground truth was "based on a group of measurements performed by intended users (i.e., Board certified cardiologists and cardiac sonographers) of the Ultrasound Systems as part of Standard of Care TTE exam per ASE guidelines at a large US-based hospital." This implies a consensus or expert-driven process for establishing the ground truth, but the specific mechanics of how disagreements were resolved are not detailed.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    The document does not indicate that a multi-reader multi-case (MRMC) comparative effectiveness study was done to compare human readers with and without AI assistance. The study focuses solely on the standalone performance of the AI algorithm in automatically detecting touchscreens.

    6. Standalone (Algorithm Only) Performance

    Yes, a standalone (algorithm only) performance study was done. The study evaluated the accuracy with which the Smart Doppler View ID algorithm could automatically recommend the correct Doppler Calculation Package group. The reported accuracy of 97.5% (95% CI 96.3%, 98.3%) refers to this standalone performance.

    7. Type of Ground Truth Used

    The ground truth used was expert consensus based on the "Standard of Care obtained group of measurements (touch screens)" and "measurements performed by intended users (i.e., Board certified cardiologists and cardiac sonographers) of the Ultrasound Systems as part of Standard of Care TTE exam per ASE guidelines." This ground truth was mapped to the appropriate touchscreen groups.

    8. Sample Size for the Training Set

    The document explicitly states: "The clinical performance study were completely distinct from that used during training of the algorithm, and there was no overlap between the two data sets." However, it does not provide the sample size for the training set.

    9. How the Ground Truth for the Training Set Was Established

    The document does not provide information on how the ground truth for the training set was established. It only mentions that the test set was distinct from the training set.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1